<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33278800</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2352-3964</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><PubDate><Year>2021</Year><Month>Jan</Month></PubDate></JournalIssue><Title>EBioMedicine</Title><ISOAbbreviation>EBioMedicine</ISOAbbreviation></Journal><ArticleTitle>Linking neuroinflammation to motor neuron degeneration in ALS: The critical role of CXCL13/CXCR5.</ArticleTitle><Pagination><StartPage>103149</StartPage><MedlinePgn>103149</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">103149</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ebiom.2020.103149</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2352-3964(20)30525-9</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arnoux</LastName><ForeName>Aliz&#xe9;e</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes centraux et p&#xe9;riph&#xe9;riques de la neurod&#xe9;g&#xe9;n&#xe9;rescence, U1118, INSERM, Strasbourg, France; Laboratoire de pharmacologie et toxicologie neurocardiovasculaire, UR7296, Universit&#xe9; de Strasbourg, Strasbourg, France; Domain Therapeutics, Illkirch-Graffenstaden, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupuis</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>M&#xe9;canismes centraux et p&#xe9;riph&#xe9;riques de la neurod&#xe9;g&#xe9;n&#xe9;rescence, U1118, INSERM, Strasbourg, France. Electronic address: ldupuis@unistra.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>EBioMedicine</MedlineTA><NlmUniqueID>101647039</NlmUniqueID><ISSNLinking>2352-3964</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C110663">CXCL13 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054382">Chemokine CXCL13</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054380">Receptors, CXCR5</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054382" MajorTopicYN="N">Chemokine CXCL13</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="N">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054380" MajorTopicYN="N">Receptors, CXCR5</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Declaration of Competing Interests A.A. reports personal fees from Domain Therapeutics, outside the submitted work. LD reports no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>5</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33278800</ArticleId><ArticleId IdType="pmc">PMC7718438</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2020.103149</ArticleId><ArticleId IdType="pii">S2352-3964(20)30525-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2013;930. 03.</Citation><ArticleIdList><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Dorst J, Dreyhaupt J, Weishaupt JH, Kassubek J, Weiland U. Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol. 2020;87(2):206&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">31849093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban J, S&#xe1;mano C, Mladinic M, Munitic I. Glia in amyotrophic lateral sclerosis and spinal cord injury: common therapeutic targets. Croat Med J. 2019;60(April(2)):109&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509626</ArticleId><ArticleId IdType="pubmed">31044582</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 2011;29(August 10(9)):824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Komine O, Yamanaka K. Neuroinflammation in motor neuron disease. Nagoya J Med Sci. 2015;77(November(4)):537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4664586</ArticleId><ArticleId IdType="pubmed">26663933</ArticleId></ArticleIdList></Reference><Reference><Citation>Trolese MC, Mariani A, Terao M, de Paola M, Fabbrizio P, Sironi F. CXCL13/CXCR5 signalling is pivotal to preserve motor neurons in amyotrophic lateral sclerosis. EBioMedicine. 2020;62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7670099</ArticleId><ArticleId IdType="pubmed">33161233</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Iennaco R, Fusi N, Heath PR, Marino M, Trolese MC. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Brain. 2013;136(November 1(11)):3305&#x2013;3332.</Citation><ArticleIdList><ArticleId IdType="pubmed">24065725</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang B-C, Cao D-L, Zhang X, Zhang Z-J, He L-N, Li C-H. CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J Clin Invest. 2016;126(February(2)):745&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4731172</ArticleId><ArticleId IdType="pubmed">26752644</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellebjerg F, B&#xf6;rnsen L, Khademi M, Krakauer M, Olsson T, Frederiksen JL. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology. 2009;73(December 8(23)):2003&#x2013;2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">19996075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagaeva LV, Rao P, Powers JM, Segal BM. CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis. J Immunol. 2006;176(June 15(12)):7676&#x2013;7685.</Citation><ArticleIdList><ArticleId IdType="pubmed">16751415</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>